Crossmark

A QSP Model for Predicting Clinical Responses to Monotherapy, Combination and Sequential Therapy Following CTLA-4, PD-1, and PD-L1 Checkpoint Blockade

Crossref DOI link: https://doi.org/10.1038/s41598-019-47802-4

Published Online: 2019-08-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Milberg, Oleg

Gong, Chang

Jafarnejad, Mohammad https://orcid.org/0000-0002-1550-0011
Bartelink, Imke H.

Wang, Bing

Vicini, Paolo

Narwal, Rajesh

Roskos, Lorin

Popel, Aleksander S.
Funding

Funding for this research was provided by:

MedImmune

U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA138264, R01 CA138264, R01 CA138264)
License Information

Text and Data Mining valid from 2019-08-02

Version of Record valid from 2019-08-02
More Information

Article History

Received: 25 February 2019

Accepted: 24 July 2019

First Online: 2 August 2019

Competing Interests

: The authors declare no competing interests.

Document is current

Any future updates will be listed below